N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease

European Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2011, Pages 2224-2235

  González Muñoz, Gema C ^a   Arce, Mariana P ^a   López, Beatriz ^a   Pérez, Concepción ^a   Romero, Alejandro ^b,c   Barrio, Laura Del ^b,c   Martín De Saavedra, María Dolores ^b,c   Egea, Javier ^b,c   León, Rafael ^b,c   Villarroya, Mercedes ^b,c   López, Manuela G ^b,c,d   García, Antonio G ^b,c,e   Conde, Santiago ^a   Rodríguez Franco, María Isabel ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Alzheimer's disease; Beta amyloid peptide; Butyrylcholinesterase inhibition; Calcium modulation; N Acylaminophenothiazines; Neuroprotection; Okadaic acid; Oxidative stress

Indexed keywords

2 (DIMETHYLAMINO) N (10H PHENOTHIAZIN 10 YL)ACETAMIDE; 3 (4 METHYLPIPERAZIN 1 YL) N (10H PHENOTHIAZIN 10 YL)PROPANAMIDE; 3 (4 METHYLPIPERAZIN 1 YL) N (3 NITRO 10H PHENOTHIAZIN 10 YL)PROPANAMIDE; 3 (4 METHYLPIPERAZIN 1 YL) N' {2 [(2 NITROPHENYL)THIO]PHENYL}PROPANEHYDRAZIDE; AMINO ACID DERIVATIVE; N (1 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (PIPERIDIN 1 YL)ACETAMIDE; N (10H PHENOTHIAZIN 10 YL) 2 (PIPERIDIN 1 YL)ACETAMIDE; N (10H PHENOTHIAZIN 10 YL) 2 (PYRROLIDIN 1 YL)ACETAMIDE; N (10H PHENOTHIAZIN 10 YL) 3 (PYRROLIDIN 1 YL)PROPANAMID; N (2 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (DIMETHYLAMINO) ACETAMIDE; N (2 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (PIPERIDIN 1 YL)ACETAMIDE; N (2 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (PYRROLIDIN 1 YL)ACETAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (DIMETHYLAMINO)ACETAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (PIPERIDIN 1 YL)ACETAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 2 (PYRROLIDIN 1 YL)ACETAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 3 (4 METHYLPIPERAZIN 1 YL)PROPANAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL) 3 (PYRROLIDIN 1 YL)PROPANAMIDE; N (3 CHLORO 10H PHENOTHIAZIN 10 YL)ACETAMIDE; N (3 METHOXY 10H PHENOTHIAZIN 10 YL) 3 (4 METHYLPIPERAZIN 1 YL)PROPANAMIDE; N (3 METHOXY 10H PHENOTHIAZIN 10 YL) 3 (PYRROLIDIN 1 YL)PROPANAMIDE; N' {2 [(4 CHLORO 2 NITROPHENYL)THIO]PHENYL} 3 (4 METHYLPIPERAZIN 1 YL)PROPANEHYDRAZIDE; N' {2 [(4 CHLORO 2 NITROPHENYL)THIO]PHENYL} 3 (PYRROLIDIN 1 YL)PROPANEHYDRAZIDE; N' {2 [(4 METHOXY 2 NITROPHENYL)THIO]PHENYL} 3 (4 METHYLPIPERAZIN 1 YL)PROPANEHYDRAZIDE; N' {2 [(4 METHOXY 2 NITROPHENYL)THIO]PHENYL} 3 (PYRROLIDIN 1 YL)PROPANEHYDRAZIDE; N'' {2 [(2 NITROPHENYL)THIO]PHENYL} 3 (PYRROLIDIN 1 YL)PROPANEHYDRAZIDE; PHENOTHIAZINE DERIVATIVE; UNCLASSIFIED DRUG; {2 [(2 NITROPHENYL)THIO]PHENYL}HYDRAZINE; {2 [(2,4 DINITROPHENYL)THIO]PHENYL}HYDRAZINE; {2 [(4 CHLORO 2 NITROPHENYL)THIO]PHENYL}HYDRAZINE; {2 [(4 METHOXY 2 NITROPHENYL)THIO]PHENYL}HYDRAZINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG INHIBITION; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYPERPHOSPHORYLATION; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; PHOSPHORYLATION;

EID: 79955575049     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.03.003     Document Type: Article

References (69)

1. P. Coleman, H. Federoff, R. Kurlan, A focus on the synapse for neuroprotection in Alzheimer disease and other dementias, Neurology 63 (2004) 1155-1162. (Pubitemid 39350010)
2. P.D. Sloane, S. Zimmerman, C. Suchindran, P. Reed, L. Wang, M. Boustani, S. Sudha, The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances, Annu. Rev. Public Health 23 (2002) 213-231.
3. H.W. Querfurth, F.M. LaFerla, Alzheimer's disease, N. Engl. J. Med. 362 (2010) 329-344.
4. S. Merlo, S. Spampinato, P.L. Canonico, A. Copani, M.A. Sortino, Alzheimer's disease: brain expression of a metabolic disorder? Trends Endocrinol. Metab. 21 (2010) 537-544.
5. J. Götz, L.M. Ittner, Y.A. Lim, Common features between diabetes mellitus and Alzheimer's disease, Cell Mol. Life Sci. 66 (2009) 1321-1325.
6. Z.S. Tan, R.S. Vasan, Thyroid function and Alzheimer's disease, J. Alzheimers Dis. 16 (2009) 503-507.
7. M.P. Mattson, Pathways towards and away from Alzheimer's disease, Nature 430 (2004) 631-639. (Pubitemid 39061671)
8. L.M. Sayre, G. Perry, M.A. Smith, Oxidative stress and neurotoxicity, Chem. Res. Toxicol. J21 (2008) 172-188. (Pubitemid 351219718)
9. P.I. Moreira, C. Carvalho, X. Zhu, M.A. Smith, G. Perry, Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology, Biochim. Biophys. Acta 1802 (2010) 2-10.
10. A.I. Bush, The metallobiology of Alzheimer's disease, Trends Neurosci. 26 (2003) 207-214. (Pubitemid 36412003)
11. B.J. Tabner, O.M. El-Agnaf, S. Turnbull, M.J. German, K.E. Paleologou, Y. Hayashi, L.J. Cooper, N.J. Fullwood, D. Allsop, Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia, J. Biol. Chem. 280 (2005) 35789-35792.
12. M.A. Lovell, W.R. Markesbery, Amyloid beta peptide, 4-hydroxynonenal and apoptosis, Curr. Alzheimer Res. 3 (2006) 359-364. (Pubitemid 44351479)
13. K.V. Kuchibhotla, S.T. Goldman, C.R. Lattarulo, H.Y. Wu, B.T. Hyman, B.J. Bacskai, Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks, Neuron 59 (2008) 214-225. (Pubitemid 352033686)
14. A.V. Terry, J.J. Buccafusco, The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development, J. Pharmacol. Exp. Ther. 306 (2003) 821-827. (Pubitemid 37025286)
15. E. Scarpini, P. Scheltens, H. Feldman, Treatment of Alzheimer's disease; current status and new perspectives, Lancet Neurol. 2 (2003) 539-547. (Pubitemid 36994993)
16. E.K. Perry, R.H. Perry, G. Blessed, B.E. Tomlinson, Changes in brain cholinesterases in senile dementia of Alzheimer type, Neuropathol. Appl. Neurobiol. 4 (1978) 273-277. (Pubitemid 9001675)
17. J.R. Atack, C. May, J.A. Kaye, A.D. Kay, S.I. Rapoport, Cerebrospinal fluid cholinesterases in aging and in dementia of the Alzheimer type, Ann. Neurol. 23 (1988) 161-167.
18. S. Darvesh, D.A. Hopkins, Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus, J. Comp. Neurol. 463 (2003) 25-43.
19. N.H. Greig, T. Utsuki, Q. Yu, X. Zhu, H.W. Holloway, T. Perry, B. Lee, D.K. Ingram, D.K. Lahiri, A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase, Curr. Med. Res. Opin. 17 (2001) 159-165. (Pubitemid 34003119)
20. M. Katalinić, G. Rusak, J. Domaćinović Barović, G. Sinko, D. Jelić, R. Antolović, Z. Kovarik, Structural aspects of flavonoids as inhibitors of human butyrylcholinesterase, Eur. J. Med. Chem. 45 (2010) 186-192.
21. S. Darvesh, I.R. Pottie, K.V. Darvesh, R.S. McDonald, R. Walsh, S. Conrad, A. Penwell, D. Mataija, E. Martin, Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants, Bioorg. Med. Chem. 18 (2010) 2232-2244.
22. S. Darvesh, R.S. McDonald, K.V. Darvesh, D. Mataija, S. Conrad, G. Gomez, R. Walsh, E. Martin, Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine, Bioorg. Med. Chem. 15 (2007) 6367-6378. (Pubitemid 47212737)
23. M.L. Bolognesi, M. Rosini, V. Andrisano, M. Bartolini, A. Minarini, V. Tumiatti, C. Melchiorre, MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond, Curr. Pharm. Des. 15 (2009) 601-613.
24. M.I. Fernández-Bachiller, C. Pérez, G.C. González-Muñoz, S. Conde, M.G. López, M. Villarroya, A.G. García, M.I. Rodríguez-Franco, Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties, J. Med. Chem. 53 (2010) 4927-4937.
25. M.P. Arce, M.I. Rodríguez-Franco, G.C. González- Muñoz, C. Pérez, B. López, M. Villarroya, M.G. López, A.G. García, S. Conde, Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease, J. Med. Chem. 52 (2009) 7249-7257.
26. M.I. Fernández-Bachiller, C. Pérez, N.E. Campillo, J.A. Páez, G.C. González-Muñoz, P. Usán, E. García-Palomero, M.G. López, M. Villarroya, A.G. García, A. Martínez, M.I. Rodríguez-Franco, Tacrineemelatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties, ChemMedChem 4 (2009) 828-841.
27. M.I. Rodríguez-Franco, M.I. Fernández-Bachiller, C. Pérez, B. Hernández-Ledesma, B. Bartolomé, Novel tacrineemelatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties, J. Med. Chem. 49 (2006) 459-462. (Pubitemid 43157478)
28. M.I. Rodríguez-Franco, M.I. Fernández-Bachiller, C. Pérez, A. Castro, A. Martínez, Design and synthesis of N-benzylpiperidine purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase, Bioorg. Med. Chem. 13 (2005) 6795-6802.
29. C. Spuch, D. Antequera, M.I. Fernández-Bachiller, M.I. Rodríguez-Franco, E. Carro, A new tacrineemelatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease, Neurotox. Res. 17 (2010) 421-431.
30. S. Conde, A. Martínez, D.I. Pérez, C. Pérez, F.J. Moreno, Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3beta) from a library of compound searching, J. Med. Chem. 46 (2003) 4631-4633.
31. D.I. Pérez, S. Conde, C. Pérez, C. Gil, D. Simon, F. Wandosell, F.J. Moreno, J.L. Gelpí, F.J. Luque, A. Martínez, Thienylhalomethylketones: irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools, Bioorg. Med. Chem. 17 (2009) 6914-6925.
32. G.C. González-Muñoz, M.P. Arce, B. López, C. Pérez, M. Villarroya, M.G. López, A.G. García, S. Conde, M.I. Rodríguez-Franco, Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow's neuroprotective therapies against neurodegenerative diseases, Eur. J. Med. Chem. 45 (2010) 6152-6158.
33. C. Corral, J. Lissavetzky, Procedimiento de preparación de 10-(γ-dialquilamino) propilamino fenotiazinas, Spanish Patent ES472157, 1978.
34. C. Corral, J. Lissavetzky, G. Quintanilla, Analogs of antipsychotic phenothiazines. 10-(β-Dialkylamino)ethylaminophenothiazines, J. Heterocycl. Chem. 15 (1978) 969-975.
35. G.L. Ellman, K.D. Courteney, V. Andres Jr., R.M. Feather-Stone, A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol. 7 (1961) 88-95.
36. M. Cyglerm, J.D. Scharg, J.L. Sussman, M. Harel, I. Silman, M.K. Gentry, B.P. Doctor, Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins, Protein Sci. 2 (1993) 366-382.
37. C. Corral, J. Lissavetzky, G. Quintanilla, Synthesis of 10-aminophenothiazines and derivatives, J. Heterocycl. Chem. 15 (1978) 1137-1140.
38. K. Itoh, S. Sakai, Y. Ishii, Reactions of group 4 organometallic compounds. 1. Reaction of trimethylsilyldialkylamines with beta-propiolactone, J. Org. Chem. 31 (1966) 3948-3951.
39. J. Bosch, T. Roca, J. Domènech, M. Suriol, Synthesis of water-soluble phenytoin prodrugs, Bioorg. Med. Chem. Lett. 9 (1999) 1859-1862. (Pubitemid 29287402)
40. J. March, in: J. March (Ed.), Advanced Organic Chemistry, 3th ed. John Wiley and Sons, Inc., New York, 1985, p. 607.
41. N. Greig, T. Utsuki, D. Ingram, Y. Wang, G. Pepeu, C. Scali, Q. Yu, J. Mamczarz, H. Holloway, T. Giordano, D. Chen, K. Furukawa, K. Sambamurti, A. Brossi, D. Lahiri, Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent, Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 17213-17218.
42. I. Manoharan, A. Kuznetsova, J.D. Fisk, R. Boopathy, O. Lockridge, S. Darvesh, Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase, J. Neural Transm. 114 (2007) 939-945. (Pubitemid 47013597)
43. L. Di, E.H. Kerns, K. Fan, O.J. McConnell, G.T. Carter, High throughput artificial membrane permeability assay for blood-brain barrier, Eur. J. Med. Chem. 38 (2003) 223-232. (Pubitemid 36349665)
44. E. Viayna, T. Gómez, C. Galdeano, L. Ramírez, M. Ratia, A. Badia, M.V. Clos, E. Verdaguer, F. Junyent, A. Camins, M. Pallàs, M. Bartolini, F. Mancini, V. Andrisano, M.P. Arce, M.I. Rodríguez-Franco, A. Bidon-Chanal, F.J. Luque, P. Camps, D. Muñoz-Torrero, Novel huprine derivatives with inhibitory activity toward b-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates, ChemMedChem 5 (2010) 1855-1870.
45. P. Camps, X. Formosa, C. Galdeano, D. Muñoz-Torrero, L. Ramírez, E. Gómez, N. Isambert, R. Lavilla, A. Badia, M.V. Clos, M. Bartolini, F. Mancini, V. Andrisano, M.P. Arce, M.I. Rodríguez-Franco, O. Huertas, T. Dafni, F.J. Luque, Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds, J. Med. Chem. 52 (2009) 5365-5379.
46. J. Marco-Contelles, R. León, C. de los Ríos, A. Samadi, M. Bartolini, V. Andrisano, O. Huertas, X. Barril, F.J. Luque, M.I. Rodríguez-Franco, B. López, M.G. López, A.G. García, M.C. Carreiras, M. Villarroya, Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease, J. Med. Chem. 52 (2009) 2724-2732.
47. F. Reviriego, M.I. Rodríguez-Franco, P. Navarro, E. García-España, M. Liu-González, B. Verdejo, A. Domènech, The sodium salt of diethyl 1 H-pyrazole-3,5-dicarboxylate as an efficient amphiphilic receptor for dopamine and amphetamines. Crystal structure and solution studies, J. Am. Chem. Soc. 128 (2006) 16458-16459.
48. F.J. Pavón, L. Hernández-Folgado, A. Bilbao, A. Cippitelli, N. Jagerovic, G. Abellán, M.I. Rodríguez-Franco, A. Serrano, M. Macías, M. Navarro, P. Goya, F. Rodríguez de Fonseca, Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole-LH 21, Neuropharmacology 51 (2006) 358-366.
49. K. Newhouse, S.L. Hsuan, S.H. Chang, B. Cai, Y. Wang, Z. Xia, Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells, Toxicol. Sci. 79 (2004) 137-146.
50. 2+ oscillations induced by veratridine, Eur. J. Pharmacol. 270 (1994) 331-339.
51. C. Orozco, A.M. García-de-Diego, E. Arias, J.M. Hernández-Guijo, A.G. García, M. Villarroya, M.G. López, Depolarization preconditioning produces cytoprotection against veratridine-induced chromaffin cell death, Eur. J. Pharmacol. 553 (2006) 28-38.
52. R. León, C. De los Ríos, J. Marco-Contelles, M.G. López, A.G. García, M. Villarroya, Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death, Eur. J. Med. Chem. 43 (2008) 668-674.
53. T. Valero, L. Del Barrio, J. Egea, N. Cañas, A. Martínez, A.G. García, M. Villarroya, M.G. López, NP04634 p.events cell damage caused by calcium overload and mitochondrial disruption in bovine chromaffin cells, Eur. J. Pharmacol. 607 (2009) 47-53.
54. J. Egea, A.O. Rosa, A. Cuadrado, A.G. García, M.G. López, Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress, J. Neurochem. 102 (2007) 1842-1852. (Pubitemid 47329263)
55. C. Supnet, I. Bezprozvanny, The dysregulation of intracellular calcium in Alzheimer disease, Cell Calcium 47 (2010) 183-189.
56. M.F. Cano-Abad, M. Villarroya, A.G. García, N.H. Gabilan, M.G. López, Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death, J. Biol. Chem. 276 (2001) 39695-39704.
57. M.F. Cano-Abad, M.G. López, J.M. Hernández-Guijo, P. Zapater, L. Gandía, P. Sánchez-García, A.G. García, Effects of the neuroprotectant lubeluzole on the cytotoxic actions of veratridine, barium, ouabain and 6-hydroxydopamine in chromaffin cells, Br. J. Pharmacol. 124 (1998) 1187-1196. (Pubitemid 28333942)
58. D. Uberti, C. Rizzini, P.F. Spano, M. Memo, Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line, Neurosci. Lett. 235 (1997) 149-153.
59. Z. Zhang, J.W. Simpkins, An okadaic acid-induced model of tauopathy and cognitive deficiency, Brain Res. 1359 (2010) 233-246.
60. M. Pérez, F. Hernández, A. Gómez-Ramos, M. Smith, G. Perry, J. Ávila, Formation of aberrant phosphotau fibrillar polymers in neural cultured cells, Eur. J. Biochem. 269 (2002) 1484-1489.
61. G. Hübinger, S. Geis, S. LeCorre, S. Mühlbacher, S. Gordon, R.P. Fracasso, F. Hoffman, S. Ferrand, H.W. Klafki, H.M. Roder, Inhibition of PHF-like tau hyperphosphorylation in SH-SY5Y cells and rat brain slices by K252a, J. Alzheimers Dis. 13 (2008) 281-294. (Pubitemid 352039036)
62. Z. Zhang, J.W. Simpkins, Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner, Brain Res. 1345 (2010) 176-181.
63. E. Arias, S. Gallego-Sandín, M. Villarroya, A.G. García, M.G. López, Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors, J. Pharmacol. Exp. Ther. 315 (2005) 1346-1353.
64. J.T. Jarrett, E.P. Berger, P.T. Lansbury Jr., The C-terminus of the beta protein is critical in amyloidogenesis, Ann. N.Y. Acad. Sci. 695 (1993) 144-148. (Pubitemid 23348252)
65. S. Conde, M.I. Rodríguez-Franco, G.C. González-Muñoz, M.P. Arce, M. Villarroya, M.G. López, A.G. García, Hydrazides of heterocyclic systems and use thereof in the treatment of neurodegenerative diseases, PCT/ES2009/070229 (2009/06/16), WO 2009/156535 A1.
66. Compound 6 was not described before.
67. C.P. LeBel, H. Ischiropoulos, S.C. Bondy, Evaluation of the probe 2′,7′ dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress, Chem. Res. Toxicol. 5 (1992) 227-231.
68. W. Zheng, D. Rampe, D.J. Triggle, Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel non-dihydropyridine Ca channel activator, in cardiac and vascular preparations, Mol. Pharmacol. 40 (1991) 734-741.
69. F. Denizot, R. Lang, Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability, J. Immunol. Methods 89 (1986) 271-277.